Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

422
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
422
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

299
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
299
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

454
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
454
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

464
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
464
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

600
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
600
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

466
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
466

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimum noninferiority dose for phase I clinical trials with immunotherapy.

Biometrics·2026
Same author

Denervation induces rapid bone degeneration concurrent to neurovascular and mechanical changes.

Bone·2026
Same author

Patient Retreat in Dose Escalation for Phase I Clinical Trials With Rare Diseases.

Statistics in medicine·2026
Same author

Evaluation of trabecular and subentheseal bone volume density in calcaneus with dual-echo ultrashort echo time magnetic resonance imaging: In vivo feasibility study.

Bone·2025
Same author

Decision Tables for Calibration-Free Odds Design in Phase I Clinical Trials.

JCO precision oncology·2025
Same author

Bayesian generalized method of moments applied to pseudo-observations in survival analysis.

Lifetime data analysis·2025

Related Experiment Video

Updated: Dec 12, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K

Restricted mean survival time for interval-censored data.

Chenyang Zhang1, Yuanshan Wu2, Guosheng Yin1

  • 1Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong, China.

Statistics in Medicine
|August 9, 2020
PubMed
Summary

We developed a new method to measure treatment effects using interval-censored restricted mean survival time (RMST). This model-free approach accurately estimates survival differences, offering a valuable tool for clinical trial analysis.

Keywords:
interval censoringnonparametric estimatorperturbation resamplingrestricted mean survival timetwo-sample test

More Related Videos

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K
Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Survival Analysis

Background:

  • Restricted mean survival time (RMST) is a model-free measure of treatment effect for right-censored data.
  • Interval censoring, common in clinical trials, presents challenges for traditional survival analysis.
  • Existing methods struggle to accurately assess treatment effects with interval-censored data.

Purpose of the Study:

  • To propose a novel, model-free measure for interval-censored restricted mean survival time (RMST).
  • To develop a hypothesis testing procedure for assessing survival differences in the presence of interval censoring.
  • To provide a clinically meaningful alternative to existing methods for analyzing interval-censored survival data.

Main Methods:

  • Developed a new interval-censored RMST estimator using linear smoothing techniques.
  • Constructed a hypothesis testing procedure to compare survival distributions between two groups.
  • Validated the proposed methods through extensive simulation studies.

Main Results:

  • The proposed interval-censored RMST estimator demonstrated negligible bias.
  • The hypothesis testing procedure showed promising performance in terms of size and power.
  • The methods were successfully applied to two real-world datasets with interval-censored observations.

Conclusions:

  • The novel interval-censored RMST measure and associated testing procedure are effective and reliable.
  • This approach offers a robust alternative for analyzing treatment effects in clinical trials with interval-censored data.
  • The proposed methods enhance the ability to detect clinically significant survival differences.